| Medical and Health Sciences | 2021-2025 | 850 | ES 19 | 99.80 |
| Epidemiology | Lifetime | 244 | ES 6 | 99.69 |
| Infectious Diseases | Lifetime | 99 | ES 2 | 99.69 |
| Emergency Medical Services | Lifetime | 171 | ES 1 | 98.25 |
| Clinical Biochemistry | Lifetime | 237 | ES 7 | 95.81 |
| Critical Care and Intensive Care Medicine | Lifetime | 302 | ES 4 | 93.88 |
| Molecular Medicine | Lifetime | 564 | ES 21 | 76.45 |
| Epidemiology | 2021-2025 | 79 | ES 4 | 99.56 |
| Infectious Diseases | 2021-2025 | 57 | ES 1 | 99.16 |
| Clinical Biochemistry | 2021-2025 | 17 | ES 2 | 94.25 |
| Emergency Medical Services | 2021-2025 | 139 | ES 2 | 82.82 |
| Pneumocystis jirovecii pneumonia detection and treatment | Lifetime | 46 | ES 3 | 99.55 |
| Antifungal resistance and susceptibility | Lifetime | 52 | ES 4 | 99.67 |
| Infective Endocarditis Diagnosis and Management | Lifetime | 66 | ES 3 | 99.66 |
| Streptococcal Infections and Treatments | Lifetime | 69 | ES 2 | 99.39 |
| Fungal Infections and Studies | Lifetime | 56 | ES 3 | 99.52 |
| Infectious Diseases and Mycology | Lifetime | 55 | ES 4 | 98.97 |
| Antimicrobial Resistance in Staphylococcus | Lifetime | 138 | ES 5 | 99.26 |
| Bacterial Identification and Susceptibility Testing | Lifetime | 126 | ES 5 | 99.23 |
| Nosocomial Infections in ICU | Lifetime | 77 | ES 8 | 99.20 |
| Central Venous Catheters and Hemodialysis | Lifetime | 148 | ES 4 | 98.72 |
| Antibiotic Use and Resistance | Lifetime | 146 | ES 6 | 98.94 |
| Cytomegalovirus and herpesvirus research | Lifetime | 465 | ES 5 | 97.95 |
| Pneumonia and Respiratory Infections | Lifetime | 583 | ES 29 | 98.06 |
| Polyomavirus and related diseases | Lifetime | 306 | ES 8 | 97.38 |
| Antibiotic Resistance in Bacteria | Lifetime | 885 | ES 36 | 97.67 |
| Clostridium difficile and Clostridium perfringens research | Lifetime | 434 | ES 9 | 96.93 |
| Transplantation: Methods and Outcomes | Lifetime | 643 | ES 10 | 97.01 |
| Nail Diseases and Treatments | Lifetime | 889 | ES 24 | 93.99 |
| SARS-CoV-2 detection and testing | Lifetime | 953 | ES 22 | 89.58 |
| Surgical site infection prevention | Lifetime | 761 | ES 23 | 90.17 |
| Infectious Aortic and Vascular Conditions | Lifetime | 727 | ES 7 | 90.15 |
| Actinomycetales infections and treatment | Lifetime | 456 | ES 15 | 81.83 |
| Medical and Biological Ozone Research | Lifetime | 995 | ES 25 | 77.94 |
| Antimicrobial Resistance in Staphylococcus | 2021-2025 | 2 | ES 1 | 99.59 |
| Infective Endocarditis Diagnosis and Management | 2021-2025 | 39 | ES 2 | 99.45 |
| Bacterial Identification and Susceptibility Testing | 2021-2025 | 23 | ES 3 | 98.59 |
| Streptococcal Infections and Treatments | 2021-2025 | 38 | ES 2 | 97.02 |
| Antifungal resistance and susceptibility | 2021-2025 | 63 | ES 4 | 98.42 |
| Fungal Infections and Studies | 2021-2025 | 112 | ES 6 | 96.61 |
| Nosocomial Infections in ICU | 2021-2025 | 75 | ES 11 | 94.26 |
| Pneumocystis jirovecii pneumonia detection and treatment | 2021-2025 | 211 | ES 6 | 90.95 |
| SARS-CoV-2 detection and testing | 2021-2025 | 827 | ES 21 | 88.25 |
| Central Venous Catheters and Hemodialysis | 2021-2025 | 355 | ES 10 | 87.30 |
| Clostridium difficile and Clostridium perfringens research | 2021-2025 | 477 | ES 6 | 86.31 |
| Orthopedic Infections and Treatments | 2021-2025 | 952 | ES 14 | 86.19 |
| Infectious Aortic and Vascular Conditions | 2021-2025 | 196 | ES 2 | 82.41 |
| Surgical site infection prevention | 2021-2025 | 368 | ES 11 | 77.17 |
| Infectious Diseases and Mycology | 2021-2025 | 287 | ES 8 | 77.93 |
| Nail Diseases and Treatments | 2021-2025 | 715 | ES 21 | 74.33 |
| Bacillus and Francisella bacterial research | 2021-2025 | 646 | ES 15 | 70.08 |
| Enterobacteriaceae and Cronobacter Research | 2021-2025 | 513 | ES 16 | 50.94 |
